title: Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion.
abstract: OBJECTIVE
  To evaluate the effect of early intravitreal bevacizumab application in patients with macular oedema due to non-ischaemic branch retinal vein occlusion (BRVO).
  
  
  METHODS
  The study included 21 patients (21 eyes) with macular oedema due to non-ischaemic BRVO. Inclusion criteria were significant macular oedema as measured by optical coherence tomography, loss of visual acuity and leakage in fluorescence angiography. All patients received 3 intravitreal injections of 1.5 mg bevacizumab. The mean follow-up was 6.2 +/- 1.2 months (mean +/- standard deviation). The mean duration of the BRVO prior to treatment was 9.2 +/- 5.4 days.
  
  
  RESULTS
  The visual acuity improved significantly from baseline 0.81 +/- 0.53 logMAR to 0.54 +/- 0.47 logMAR (p < 0.001) at 1 month, 0.55 +/- 0.46 (p = 0.001) at 3 months and to 0.55 +/- 0.49 (p = 0.002) at 6 months after the first injection. The mean central retinal thickness decreased significantly (p < 0.001) from 492 +/- 113 microm at baseline to 294 +/- 117 microm at 1 month after the first injection to 325 +/- 127 microm at 3 months (p < 0.001) and to 316 +/- 117 microm at 6 months (p < 0.001) after the first injection. The increase in visual acuity correlated significantly (p < 0.01) with the decrease in macular thickness.
  
  
  CONCLUSIONS
  Early intravitreal injection of bevacizumab may decrease macular oedema and improve visual acuity in eyes with non-ischaemic BRVO.
authors.affiliation: Department of Ophthalmology, Ruprecht Karls University, Heidelberg, Germany.
authors.forename: Florian
authors.initials: F
authors.lastname: Rensch
authors.forename: Jost B
authors.initials: JB
authors.lastname: Jonas
authors.forename: Ulrich H M
authors.initials: UH
authors.lastname: Spandau
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005500:Follow-Up Studies; D005584:Fovea Centralis / Q000473:pathology; D006801:Humans; D007511:Ischemia; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000187:drug effects; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab